Pharmacodynamic and pharmacokinetic studies of an insulin buccal spray formulation in rats and rabbits

Chinese Pharmaceutical Journal

Volumn 38, Issue 6, 2003, Pages 448-452

  Yang, Tian zhi ^a   Chen, Qi long ^a   Chen, Da bing ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Insulin buccal spray formulation; Pharmacodynamics; Pharmacokinetics; Relative bioavailability; Relative pharmacological bioavailability

Indexed keywords

BLOOD; DRUG PRODUCTS; GLUCOSE; INSULIN;

INSULIN BUCCAL SPRAY FORMULATION;

PHARMACOKINETICS;

GLUCOSE; INSULIN;

AEROSOL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PARAMETER; PHARMACODYNAMICS; RABBIT; RAT; TIME;

EID: 0042090922     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mitra R, Pezron I, Waihei A, et al. Lipid emulsion as vesicles for enhanced nasal delivery of insulin [J]. Int J Pharm, 2000, 205 (1-2): 127.
2. Al-Achi A, Greenwood R. Buccal administration of human insulin in streptozocin-diabetic rats [J]. Res Commun Chem Pathol Pharmacol, 1993, 82(3): 297.
3. Laube BL, Benedict WG, Dobs AS. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes [J]. Chest, 1998, 114(6): 1734.
4. Hosny EA, Ghilzai N, Najar TA. Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate [J]. Drug Dev Ind Pharm, 1998, 24(3): 307.
5. Suzuki A, Morishita M, Kajita M, et al. Enhanced colonic and rectal absorption of insulin using a multiple emulsionn containning eicosapentaenoic acid and docosahexaenoic acid [J]. J Pharm Sci, 1998, 87(10): 1196.
6. Lee VH. Enzymatic barriers to peptide and protein absorption [J]. Crit Rev Ther Drug Carrier Syst, 1988, 5(2): 69.
7. Lee VH. Peptidase activities in absorptive mucosae [J]. Biochem Soc Trans, 1989, 17(3): 937.
8. Rathbone MJ, Ponchel G, Ghazalil A. Oral Mucosal Drug Delivery [M]. New York: Marcel Dekker INC, 1996:242-253.
9. Ishida M, Machida Y, Nambu N, et al. New mucosal dosage of insulin [J]. Chem Pharm Bull, 1981, 29(3): 810.
10. Morishita M, Barichello JM, Takayama K, et al. Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin [J]. Int J Pharm, 2001, 212(1): 289.
11. Wearly LL. Recent progresses in protein and peptide delivery by noninvasive routes [J]. Crit Rev Ther Drug Carrier Syst, 1991, 8(2): 331.
12. Yamamoto A, Taniguchi T, Rikyuum K, et al. Effect of various protease inhibitors on the intestinal absorption and degradation of insulin in rats [J]. Pharm Res, 1994, 11(4): 1496.
13. Robbins DC, Andersen R. Report of the American of immunoreactive proinsulin in type II diabetes mellitus and in experiment insulin resisitance [J]. Diabetologia, 1987, 30(3): 698.
14. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review [J]. J Pharm Pharmaceut Sci, 1998, 1(1): 15.
15. Aungst BJ, Rogers NJ. Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na2EDTA and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery [J]. Pharm Res, 1988, 5(4): 305.
16. Aungst BJ, Rogers NJ. Comparison of the Effects of Various Transmucosal Absorption Promoters on Buccal Insulin Delivery [J]. Int J Pharm, 1989, 53(6): 227.